$2.52
1.18% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Leap Therapeutics, Inc. Stock price

$2.52
-1.08 30.00% 1M
+0.14 5.88% 6M
-1.63 39.20% YTD
-0.08 3.08% 1Y
-20.68 89.14% 3Y
-4.72 65.21% 5Y
-76.08 96.79% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.03 1.18%
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Key metrics

Market capitalization $96.56m
Enterprise Value $34.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.97
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-68.75m
Free Cash Flow (TTM) Free Cash Flow $-55.17m
Cash position $62.82m
EPS (TTM) EPS $-1.93
P/E forward negative
Short interest 3.13%
Show more

Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Leap Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Leap Therapeutics, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Leap Therapeutics, Inc. forecast:

Buy
100%

Financial data from Leap Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
71% 71%
-
-0.12 -0.12
71% 71%
-
- Selling and Administrative Expenses 13 13
0% 0%
-
- Research and Development Expense 56 56
23% 23%
-
-69 -69
20% 20%
-
- Depreciation and Amortization 0.12 0.12
71% 71%
-
EBIT (Operating Income) EBIT -69 -69
20% 20%
-
Net Profit -65 -65
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Leap Therapeutics, Inc. Stock News

Neutral
PRNewsWire
37 minutes ago
CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Neutral
PRNewsWire
13 days ago
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.
Neutral
PRNewsWire
about 2 months ago
CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of ca...
More Leap Therapeutics, Inc. News

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Doug Onsi
Employees 54
Founded 2011
Website www.leaptx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today